you are viewing a single comment's thread.
CDX-011 is second most advance ADC after Adcetris and would be the first validation of ADC for solid tumors.
That would be the first validation of SGEN's ADC technology for solid tumors. T-DM1 would be the first validation of any ADC in solids.
I have not heard any financial terms. I suspect they are modest, but CDX-011 does have a large market potential so some "hard" value (in addition to validation as you mentioned).
Thanks Slum and Fib.